Home » Stocks » NBSE

NeuBase Therapeutics, Inc. (NBSE)

Stock Price: $5.27 USD 0.19 (3.74%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 170.64M
Revenue (ttm) n/a
Net Income (ttm) -16.95M
Shares Out 23.17M
EPS (ttm) -3.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $5.27
Previous Close $5.08
Change ($) 0.19
Change (%) 3.74%
Day's Open 5.08
Day's Range 4.92 - 5.35
Day's Volume 366,110
52-Week Range 4.92 - 12.89

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic me...

1 week ago - GlobeNewsWire

PITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic m...

1 week ago - GlobeNewsWire

PITTSBURGH, April 22, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic me...

2 weeks ago - GlobeNewsWire

PITTSBURGH, April 21, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic me...

2 weeks ago - GlobeNewsWire

One of its investors praised the company in a quarterly performance update.

3 months ago - The Motley Fool

David Einhorn (Trades, Portfolio)'s hedge fund, Greenlight Capital, ended 2020 on a high note. After a rough start to the year, Greenlight added 25% in the fourth quarter of 2020, making it the best qua...

Other stocks mentioned: GRBK, HON, REZI
3 months ago - GuruFocus

PITTSBURGH, Jan. 11, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of syn...

3 months ago - GlobeNewsWire

Data presented throughout 2020 have validated the potential of the PATrOL™ platform to develop highly targeted therapies that increase, decrease or change causal protein function

4 months ago - GlobeNewsWire

Registration For This FREE Tribe Public Presentation and Q&A Event Is Now Open at NeuBase22.TribePublic.com SAN FRANCISCO, CA / ACCESSWIRE / December 18, 2020 / Tribe Public announced today that Dietric...

4 months ago - Accesswire

PITTSBURGH, Nov. 23, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of syn...

5 months ago - GlobeNewsWire

PITTSBURGH, Nov. 10, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of syn...

5 months ago - GlobeNewsWire

PITTSBURGH, Sept. 28, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of ...

7 months ago - GlobeNewsWire

PITTSBURGH, Sept. 17, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of ...

7 months ago - GlobeNewsWire

Strong Pharmacokinetic and Pharmacodynamic Data Presented in March Validate Platform and Position Company for Scalable Output of Synthetic Precision Genetic Medicines

8 months ago - GlobeNewsWire

NeuBase (NBSE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

About NBSE

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. Ne... [Read more...]

Industry
Biotechnology
CEO
Dietrich Stephan
Employees
15
Stock Exchange
NASDAQ
Ticker Symbol
NBSE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for NBSE stock is "Strong Buy." The 12-month stock price forecast is 16.75, which is an increase of 217.84% from the latest price.

Price Target
$16.75
(217.84% upside)
Analyst Consensus: Strong Buy